This week, we will be discussing a randomized controlled trial of eculizumab in STEC-HUS. Will eculizumab manage to surpass its well-established reputation as expensivumab and demonstrate some positive results?
ECULIZUMAB in STEC - HUS - a Visual Abstract
Is eculizumab effective in pediatric patients with Shiga toxin-related E. Coli hemolytic uremic syndrome?
Check out the visual abstract by Melvin Chan for the answer.
Top Stories in Nephrology 2023
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
Aldosterone Synthase Inhibitors in Proteinuric CKD: the Visual Abstract
Yet another new medication class for use in the RAAS cascade. BI 690517, an aldosterone synthase inhibitor, has been shown to significantly reduce proteinuria with or without empagliflozin. VA by Brian Rifkin.
